businesspress24.com - Itonis Pharmaceuticals and Charles Hensley, Ph.D. to Begin Distributing Emesyl(TM) Anti-Nausea Homeo
 

Itonis Pharmaceuticals and Charles Hensley, Ph.D. to Begin Distributing Emesyl(TM) Anti-Nausea Homeopathic Product in Mexico

ID: 1262905

(firmenpresse) - LAGUNA HILLS, CA -- (Marketwired) -- 09/12/13 -- Itonis, Inc.'s pharmaceutical division (PINKSHEETS: ITNS) and Charles Hensley, Ph.D., the inventor of the Zicam® Cold Remedy, are pleased to announce that Hensley Brothers Distribution, LLC ("HBD") will distribute Emesyl(™), the Company's over-the-counter homeopathic product for nausea relief, to Mexico through one of HBD's distribution partners.

Dr. Hensley commented, "Entering the Mexican market will open up the Central and South American markets, and we are pleased to have Emesyl(™) enter the international market at such an early stage."

Emesyl™ is the Company's anti-nausea relief product and is to be manufactured by Oasis Health Products, Inc.

Itonis Pharmaceuticals, a division of Itonis, Inc., is headed by Charles Hensley, Ph.D. This division's mission is to create and market over-the-counter and prescription homeopathic products that better people's lives. Dr. Hensley is a pioneer in the development and marketing of safe and effective therapeutic nutraceutical and homeopathic preparations. He was a founder of the company that launched the Zicam® Cold Remedy, making the product a household name and forever changing the marketing and product placement paradigm for homeopathic drugs in the United States. Dr. Hensley and his team plan to use the same methodologies to revolutionize the treatment of several other common ailments and other chronic diseases.

Itonis, Inc. was incorporated in the state of Nevada on July 5, 2005 under the name of Kenshou, Inc., which later changed to Itonis, Inc. on December 2, 2005. For more information, please visit .

Statements in this press release may constitute forward-looking statements and are subject to numerous risks and uncertainties, including the failure to complete successfully the development of new or enhanced products, the Company's future capital needs, the lack of market demand for any new or enhanced products the Company may develop, any actions by the Company's affiliates that may be adverse to the Company, the success of competitive products, other economic factors affecting the Company and its markets, seasonal changes, and other risks detailed from time to time in the Company's filings with the U.S. Securities and Exchange Commission. The actual results may differ materially from those contained in this press release. The Company disclaims any obligation to update any statements in this press release.









Contact:
Itonis, Inc.

(949) 200-8887


Themen in dieser Pressemitteilung:


Unternehmensinformation / Kurzprofil:



Leseranfragen:



PresseKontakt / Agentur:



drucken  als PDF  an Freund senden  Axxess Pharma Inc. President, Daniel Bagi, M.D. Provides Exclusive Interview on StockTradersTalk.com
Medical Pharmacies Group Acquires Desjardins Healthcare Group to Expand Its Offerings and Enhance Value to Customers
Bereitgestellt von Benutzer: Marketwired
Datum: 12.09.2013 - 06:30 Uhr
Sprache: Deutsch
News-ID 1262905
Anzahl Zeichen: 0

contact information:
Contact person:
Town:

LAGUNA HILLS, CA


Phone:

Kategorie:

Drugs


Anmerkungen:


Diese Pressemitteilung wurde bisher 240 mal aufgerufen.


Die Pressemitteilung mit dem Titel:
"Itonis Pharmaceuticals and Charles Hensley, Ph.D. to Begin Distributing Emesyl(TM) Anti-Nausea Homeopathic Product in Mexico
"
steht unter der journalistisch-redaktionellen Verantwortung von

Itonis, Inc. (Nachricht senden)

Beachten Sie bitte die weiteren Informationen zum Haftungsauschluß (gemäß TMG - TeleMedianGesetz) und dem Datenschutz (gemäß der DSGVO).


Alle Meldungen von Itonis, Inc.



 

Who is online

All members: 10 564
Register today: 1
Register yesterday: 0
Members online: 0
Guests online: 100


Don't have an account yet? You can create one. As registered user you have some advantages like theme manager, comments configuration and post comments with your name.